Literature DB >> 32474642

Pancreatic cancer treatment: better, but a long way to go.

Robert J Torphy1, Yuki Fujiwara1, Richard D Schulick2.   

Abstract

Remarkable progress has been made in treating pancreatic cancer over the past century, including refinement of our surgical techniques and improvements in adjuvant and neoadjuvant therapies. Despite these advances, the incidence of pancreatic cancer is rising globally, and it remains a deadly disease. In this review, we highlight the historical perspectives of pancreatic cancer treatment and outline the areas of future advancement that will assist progression towards better outcomes. Areas of future advancement include improving prevention strategies and early detection, refining our molecular understanding of pancreatic cancer, identifying more effective systemic therapies, and improving quality of life and surgical outcomes. Furthermore, systems need to be put in place to ensure all patients with pancreatic cancer receive high quality care and are given the appropriate options and sequence of therapy. This is best achieved through multidisciplinary care.

Entities:  

Keywords:  Adjuvant therapy; Neoadjuvant therapy; Pancreatic cancer; Pancreaticoduodenectomy

Mesh:

Year:  2020        PMID: 32474642      PMCID: PMC7837389          DOI: 10.1007/s00595-020-02028-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  60 in total

1.  A reminiscence: pancreaticduodenectomy.

Authors:  A O WHIPPLE
Journal:  Rev Surg       Date:  1963 Jul-Aug

2.  TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER.

Authors:  A O Whipple; W B Parsons; C R Mullins
Journal:  Ann Surg       Date:  1935-10       Impact factor: 12.969

3.  Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.

Authors:  Kianna Y Elahi-Gedwillo; Marjorie Carlson; Jon Zettervall; Paolo P Provenzano
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

4.  Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy.

Authors:  R Yoshioka; H Yasunaga; K Hasegawa; H Horiguchi; K Fushimi; T Aoki; Y Sakamoto; Y Sugawara; N Kokudo
Journal:  Br J Surg       Date:  2014-02-24       Impact factor: 6.939

5.  Minimally Invasive Versus Open Pancreaticoduodenectomy: A Propensity-matched Study From a National Cohort of Patients.

Authors:  Ibrahim Nassour; Sam C Wang; Alana Christie; Mathew M Augustine; Matthew R Porembka; Adam C Yopp; Michael A Choti; John C Mansour; Xian-Jin Xie; Patricio M Polanco; Rebecca M Minter
Journal:  Ann Surg       Date:  2018-07       Impact factor: 12.969

6.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

7.  Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.

Authors:  A Malesci; M A Tommasini; C Bonato; P Bocchia; M Bersani; A Zerbi; E Beretta; V Di Carlo
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.

Authors:  Dannielle D Engle; Hervé Tiriac; Keith D Rivera; Arnaud Pommier; Sean Whalen; Tobiloba E Oni; Brinda Alagesan; Eun Jung Lee; Melissa A Yao; Matthew S Lucito; Benjamin Spielman; Brandon Da Silva; Christina Schoepfer; Kevin Wright; Brianna Creighton; Lauren Afinowicz; Kenneth H Yu; Robert Grützmann; Daniela Aust; Phyllis A Gimotty; Katherine S Pollard; Ralph H Hruban; Michael G Goggins; Christian Pilarsky; Youngkyu Park; Darryl J Pappin; Michael A Hollingsworth; David A Tuveson
Journal:  Science       Date:  2019-06-21       Impact factor: 63.714

10.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.

Authors:  Richard A Moffitt; Raoud Marayati; Elizabeth L Flate; Keith E Volmar; S Gabriela Herrera Loeza; Katherine A Hoadley; Naim U Rashid; Lindsay A Williams; Samuel C Eaton; Alexander H Chung; Jadwiga K Smyla; Judy M Anderson; Hong Jin Kim; David J Bentrem; Mark S Talamonti; Christine A Iacobuzio-Donahue; Michael A Hollingsworth; Jen Jen Yeh
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

View more
  19 in total

Review 1.  Caring experiences of family caregivers of patients with pancreatic cancer: an integrative literature review.

Authors:  Yoonjoo Kim; Wonhee Baek
Journal:  Support Care Cancer       Date:  2022-01-07       Impact factor: 3.603

2.  Inhibition of glutathione metabolism can limit the development of pancreatic cancer.

Authors:  Pei-Yuan Cai; Mei-Lin Ma; Yang-Fen Zhang; Zi-Xuan Zhou; Yan Wang; Lian-Ping He; Wei Wang
Journal:  World J Stem Cells       Date:  2022-05-26       Impact factor: 5.247

3.  Deoxyelephantopin Suppresses Pancreatic Cancer Progression In Vitro and In Vivo by Targeting linc00511/miR-370-5p/p21 Promoter Axis.

Authors:  Daolin Ji; Li Hou; Chunyang Xie; Haonan Feng; Dongdong Bao; Yue Teng; Junhao Liu; Tiangang Cui; Xiuhong Wang; Yi Xu; Gang Tan
Journal:  J Oncol       Date:  2022-06-25       Impact factor: 4.501

Review 4.  The role of artificial intelligence in pancreatic surgery: a systematic review.

Authors:  D Schlanger; F Graur; C Popa; E Moiș; N Al Hajjar
Journal:  Updates Surg       Date:  2022-03-02

5.  Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy.

Authors:  Takashi Kokumai; Shuichi Aoki; Masamichi Mizuma; Shimpei Maeda; Hideo Ohtsuka; Kei Nakagawa; Takanori Morikawa; Fuyuhiko Motoi; Takashi Kamei; Michiaki Unno
Journal:  Surg Today       Date:  2021-04-07       Impact factor: 2.549

6.  Coumarin-Palladium(II) Complex Acts as a Potent and Non-Toxic Anticancer Agent against Pancreatic Carcinoma Cells.

Authors:  Aleksandra Krstic; Aleksandar Pavic; Edina Avdovic; Zoran Markovic; Milena Stevanovic; Isidora Petrovic
Journal:  Molecules       Date:  2022-03-25       Impact factor: 4.411

Review 7.  Syndecans and Pancreatic Ductal Adenocarcinoma.

Authors:  Nausika Betriu; Juan Bertran-Mas; Anna Andreeva; Carlos E Semino
Journal:  Biomolecules       Date:  2021-02-25

8.  Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreatic cancer cell lines.

Authors:  Kan Omi; Yoichi Matsuo; Goro Ueda; Yoshinaga Aoyama; Tomokatsu Kato; Yuichi Hayashi; Hiroyuki Imafuji; Kenta Saito; Ken Tsuboi; Mamoru Morimoto; Ryo Ogawa; Hiroki Takahashi; Shuji Takiguchi
Journal:  Oncol Rep       Date:  2021-03-24       Impact factor: 3.906

9.  Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer.

Authors:  Shi-Lei Liu; Hai-Bin Liang; Zi-Yi Yang; Chen Cai; Zi-You Wu; Xiang-Song Wu; Ping Dong; Mao-Lan Li; Lei Zheng; Wei Gong
Journal:  Int J Med Sci       Date:  2022-01-04       Impact factor: 3.738

10.  Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer.

Authors:  Jilong Hu; Zhinan Zheng; Jia Lei; Yuxin Cao; Qiyun Li; Zhi Zheng; Chuanjun Chen
Journal:  PPAR Res       Date:  2021-07-21       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.